Improving RLT Safety & Reducing Off-Target Toxicity Through Tumor- Selective Targeting
5:00 pm - Thursday 25th February 2027
- Identify biomarkers preferentially expressed on malignant versus healthy cells to strengthen tumor selectivity & minimize normal-tissue exposure
- Leverage molecular imaging to characterize target expression & tumor uptake and inform suitability for therapeutic development
- Translate diagnostic targeting insights into therapeutic radiopharmaceutical strategies to improve specificity & reduce off-target toxicity
- Apply lessons across prostate, breast, & bladder cancer to demonstrate how tumorselective targeting can support safer therapeutic development
